Immunotherapy plus precision radiation shows promise in advanced lung cancer
NCT ID NCT03589547
First seen Apr 04, 2026 · Last updated Apr 28, 2026 · Updated 6 times
Summary
This study tested whether adding a type of targeted radiation (SBRT) to the immunotherapy drug durvalumab could help control stage III lung cancer after standard chemotherapy and radiation. Eleven participants received the combination to see if it was safe and could delay cancer growth. The goal was to improve outcomes without increasing serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
Conditions
Explore the condition pages connected to this study.